Hudson Bay Capital Management LP Has $8.49 Million Holdings in Galapagos NV $GLPG

Hudson Bay Capital Management LP decreased its position in shares of Galapagos NV (NASDAQ:GLPG) by 69.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 245,000 shares of the biotechnology company’s stock after selling 553,400 shares during the quarter. Hudson Bay Capital Management LP owned 0.37% of Galapagos worth $8,487,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of GLPG. State of Wyoming acquired a new position in shares of Galapagos in the 2nd quarter valued at approximately $28,000. GAMMA Investing LLC lifted its holdings in shares of Galapagos by 79.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,473 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 652 shares during the period. Quadrant Capital Group LLC acquired a new stake in shares of Galapagos during the 3rd quarter worth approximately $134,000. Squarepoint Ops LLC acquired a new stake in shares of Galapagos during the 3rd quarter worth approximately $211,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Galapagos in the third quarter valued at approximately $212,000. 32.46% of the stock is owned by institutional investors.

Galapagos Price Performance

Shares of NASDAQ:GLPG opened at $32.53 on Friday. The firm has a 50 day simple moving average of $33.62 and a 200 day simple moving average of $32.85. Galapagos NV has a one year low of $22.59 and a one year high of $37.78.

Wall Street Analysts Forecast Growth

GLPG has been the subject of several research analyst reports. Royal Bank Of Canada boosted their price objective on shares of Galapagos from $32.00 to $33.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 24th. Raymond James Financial reaffirmed a “market perform” rating on shares of Galapagos in a report on Tuesday, February 24th. Weiss Ratings raised Galapagos from a “sell (d)” rating to a “hold (c)” rating in a report on Thursday, February 26th. Sanford C. Bernstein assumed coverage on Galapagos in a research report on Wednesday, November 26th. They set a “hold” rating for the company. Finally, UBS Group reaffirmed a “market perform” rating on shares of Galapagos in a research note on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Galapagos presently has an average rating of “Hold” and a consensus price target of $36.50.

About Galapagos

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.